PubMed Central, : RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2019 April; 10(2): e0012. ISSN: 2076-9172Published online 2019 April 18. doi: 10.5041/RMMJ.10366.

Table 3.

Selected Major Clinical Studies Involving HER2-targeted Therapies.

Clinical Study	Trastuzumab-Anthracycline Interval	Monitoring	Cardiac Risk-related Exclusion Criteria	Clinical Heart Failure (%)	LV Dysfunction (%)	Partial Reversibility Reported
Slamon et al.¹⁰⁷	Concurrent	None pre-specified	None	16%	27%	Yes
Romond et al.¹⁰⁹	3 weeks	MUGA	LVD, HTN, ANY	4.1%	19%^*	Yes
Polman et al.¹¹⁸	3 weeks	MUGA or ECHO	LVD, HTN, ANY	2%	19%	Yes
Goldhirsch et al.¹¹⁹	3 months	MUGA or ECHO	LVD, HTN, ANY	0.8%	7.2%	Yes
Tolaney et al.¹²⁰	No anthracycline given	MUGA or ECHO	LVD, HTN, ANY	0.5%	3.2%	Yes

^*Discontinued drug due to cardiac adverse event.

ANY, any sign or symptom of cardiac disease; ECHO, echocardiography; HTN, hypertension; LVD, left ventricular dysfunction.

RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2019 April; 10(2): e0012. ISSN: 2076-9172

Published online 2019 April 18. doi: 10.5041/RMMJ.10366